Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas C Blevins

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Journal of Diabetes Science and Technology|March 24, 2010
Professional continuous glucose monitoring in clinical practice 2010Thomas C Blevins
Postgraduate Medicine|November 30, 2016
Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitusThomas C Blevins, Azeez Farooki
Diabetes Technology & Therapeutics|February 1, 2026
Overcoming Therapeutic Inertia with Inhaled Insulin TherapyThomas C Blevins, Steve V Edelman
Diabetes, Obesity & Metabolism|April 16, 2018
Efficacy and safety of MYL-1501D vs insulin glargine in patients with type 1 diabetes after 52 weeks: Results of the INSTRIDE 1 phase III studyThomas C Blevins, Abhijit Barve, Bin Sun, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|July 15, 2004
Once-daily insulin glargine compared with twice-daily NPH insulin in patients with type 1 diabetesKenneth S Hershon, Thomas C Blevins, Christy A Mayo, et al.
The Journal of Family Practice|April 5, 2017
Hot Topics in Primary Care: Demystifying the Differences: Follow-on Biologics, Biosimilars, and GenericsEugene E Wright, Thomas C Blevins, Beverly Reed, et al.
Diabetes Technology & Therapeutics|February 1, 2026
Case Reports: Practical Use of Pulmonary Inhaled (Technosphere) Insulin in Type 1 Diabetes, Type 2 Diabetes, and PregnancyIrl B Hirsch, Thomas C Blevins, Amy M Valent, et al.
Diabetes Technology & Therapeutics|February 1, 2026
Dosing Afrezza: It's Not that ComplicatedSteve V Edelman, Thomas C Blevins, Christopher G Parkin, et al.
Diabetes Technology & Therapeutics|October 22, 2020
Fast Acting Insulin Aspart Compared with Insulin Aspart in the Medtronic 670G Hybrid Closed Loop System in Type 1 Diabetes: An Open Label Crossover StudyKerem Ozer, Alison M Cooper, Lily P Ahn, et al.
Diabetes, Obesity & Metabolism|November 7, 2019
Efficacy and safety of MYL-1501D versus insulin glargine in people with type 1 diabetes mellitus: Results of the INSTRIDE 3 phase 3 switch studyThomas C Blevins, Abhijit Barve, Yaron Raiter, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Journal of Diabetes Science and Technology|March 24, 2010
Professional continuous glucose monitoring in clinical practice 2010Thomas C Blevins
Postgraduate Medicine|November 30, 2016
Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitusThomas C Blevins, Azeez Farooki
Diabetes Technology & Therapeutics|February 1, 2026
Overcoming Therapeutic Inertia with Inhaled Insulin TherapyThomas C Blevins, Steve V Edelman
Diabetes, Obesity & Metabolism|April 16, 2018
Efficacy and safety of MYL-1501D vs insulin glargine in patients with type 1 diabetes after 52 weeks: Results of the INSTRIDE 1 phase III studyThomas C Blevins, Abhijit Barve, Bin Sun, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|July 15, 2004
Once-daily insulin glargine compared with twice-daily NPH insulin in patients with type 1 diabetesKenneth S Hershon, Thomas C Blevins, Christy A Mayo, et al.
The Journal of Family Practice|April 5, 2017
Hot Topics in Primary Care: Demystifying the Differences: Follow-on Biologics, Biosimilars, and GenericsEugene E Wright, Thomas C Blevins, Beverly Reed, et al.
Diabetes Technology & Therapeutics|February 1, 2026
Case Reports: Practical Use of Pulmonary Inhaled (Technosphere) Insulin in Type 1 Diabetes, Type 2 Diabetes, and PregnancyIrl B Hirsch, Thomas C Blevins, Amy M Valent, et al.
Diabetes Technology & Therapeutics|February 1, 2026
Dosing Afrezza: It's Not that ComplicatedSteve V Edelman, Thomas C Blevins, Christopher G Parkin, et al.
Diabetes Technology & Therapeutics|October 22, 2020
Fast Acting Insulin Aspart Compared with Insulin Aspart in the Medtronic 670G Hybrid Closed Loop System in Type 1 Diabetes: An Open Label Crossover StudyKerem Ozer, Alison M Cooper, Lily P Ahn, et al.
Diabetes, Obesity & Metabolism|November 7, 2019
Efficacy and safety of MYL-1501D versus insulin glargine in people with type 1 diabetes mellitus: Results of the INSTRIDE 3 phase 3 switch studyThomas C Blevins, Abhijit Barve, Yaron Raiter, et al.
Pageof 3